VC
GLMD icon

Voss Capital’s Galmed Pharmaceuticals GLMD Stock Holding History

Voss Capital’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-87
Closed -$443K – 46
2020
Q3 		$443K Sell
87
-6
-6% -$39.2K 0.25% 44
2020
Q2 		$640K Sell
93
-18
-16% -$121K 0.43% 33
2020
Q1 		$319K Buy
111
+6
+6% +$45.6K 0.43% 23
2019
Q4 		$870K Buy
+105
New +$722K 0.13% 80

Other funds holding GLMD

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
II
Ibex Investors Denver, Colorado $194M AUM 23.58% 1-Year Est. Return
PAWC
P.A.W. Capital Greenwich, Connecticut $131M AUM 35.16% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $65.2B AUM 31.44% 1-Year Est. Return

Voss Capital's GLMD Position: Q4 2020 in Review

Voss Capital sold out of Galmed Pharmaceuticals (GLMD) in Q4 2020, closing a stake of 87 shares — an estimated $443K sold.

Voss Capital first reported a position in GLMD in Q4 2019 and held it in 4 quarters. The position peaked at $870K in Q4 2019. 18 funds tracked by Wall St. Rank hold GLMD as of Q4 2020.

  • Voss Capital reported no remaining Galmed Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Voss Capital sold 87 Galmed Pharmaceuticals shares in Q4 2020, an estimated $443K.
  • Voss Capital first reported a position in Galmed Pharmaceuticals in Q4 2019 and held it in 4 quarters.
  • Voss Capital's Galmed Pharmaceuticals position peaked at $870K in Q4 2019.
  • 18 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q4 2020.

Based on Voss Capital's 13F filing for Q4 2020, filed 12 Feb 2021.